State-of-the-art facility to focus on next-generation biologicals and targeted therapies.
Plexuspharmaco is expanding its European footprint with a new €50M Research & Development center in Munich. The facility will employ over 200 leading scientists dedicated to advancing treatments in oncology and rare diseases. [PENDING CLIENT APPROVAL]